New Analysis of Phase 3 study presented at SUO 2020

New Data Analyses from Phase 3 Study of Investigational Gene Therapy Nadofaragene Firadenovec Presented at Society of Urologic Oncology Annual Meeting Adds More Evidence to Data Published in Lancet Oncology Low rate of cystectomy and delayed time to cystectomy among...

FerGene Provides Update on BLA for Nadofaragene Firadenovec

The U.S. Food and Drug Administration (FDA) has issued a response to the Biologics License Application (BLA) for investigational gene therapy, nadofaragene firadenovec, which was submitted by FKD Therapies Oy, the company leading the development and regulatory filing...

FerGene Appoints David Meek Chief Executive Office

CAMBRIDGE, Mass. – December 19, 2019 FerGene, a new gene therapy company launched by Ferring Pharmaceuticals and Blackstone Life Sciences in November, today announced the appointment of David Meek as President and Chief Executive Officer, effective January 14,...

FerGene announces pivotal Phase 3 study of nadofaragene firadenovec met its primary endpoint with more than half of patients with high-grade non-muscle invasive bladder cancer (CIS ± Ta/T1) achieving a complete response at three months

The multi-center study met its primary endpoint with 53% of CIS ± Ta/T1 patients achieving a complete response (CR) at three months, and 24% continuing to show a CR at 12 monthsAdditional data show 73% high-grade recurrence free (HGRF) survival in patients with...